FDA rejects Merck's Mevacor OTC bid

Share this article:

An FDA advisory panel has rejected Merck's bid to sell the cholesterol-lowering drug Mevacor without a prescription.

The panel voted 10-2 against recommending OTC sales of the drug.

The rejection marks the third time a global drugmaker has failed to win FDA approval for Mevacor's non-prescription status.

Merck's Edwin Hemwall VP, global OTC regulatory and scientific affairs. “We are disappointed in today's outcome.  We felt we presented a compelling case to the committee that non-prescription Mevacor 20 mg would be a valuable option for motivated consumers who know they have moderately elevated cholesterol and certain risk factors, and are already talking with their healthcare provider."
 
Although the FDA is not bound by its panel recommendations, it does take expert advice into consideration.  The anticipated action date by the FDA is Jan. 26, 2008.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.